



Rexahn Pharmaceuticals, Inc.
Investor Relations Department
15245 Shady Grove Road, Suite
455
Rockville, MD 20850
United States

Visit IR website [↗](#)
Sign-up for email alerts [↗](#)

AMEX: RNN

Last Trade:	2.38
Trade Time:	10:48 AM ET 01/23/18
Change:	-0.03 ↓ (1.245%)
Day Range	2.31 - 2.48
52-Week Range	1.67 - 7.10
Volume	191,105

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing best-in-class therapeutics for the treatment of cancer. Rexahn currently has three clinical stage oncology candidates, Archexin®, RX-3117, and Supinoxin™ (RX-5902) and a robust pipeline of preclinical compounds to treat multiple types of cancer.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

01/22/18

[Rexahn Pharmaceuticals Announces Poster Presentation of RX-3117 Data in Metastatic Pancreatic Patients at the American Society of Clinical Oncology Gastrointestinal Cancers \(ASCO GI\) 2018 Annual Meeting](#)

01/18/18

[Rexahn Pharmaceuticals to Present at the American Society of Clinical Oncology Gastrointestinal Cancers \(ASCO GI\) 2018 Annual Meeting](#)

01/08/18

[Rexahn Pharmaceuticals to Present at Biotech Showcase™ 2018](#)

01/04/18

[Rexahn Pharmaceuticals Announces the Appointment of Douglas J. Swirsky as President and Chief Financial Officer](#)

12/11/17

[Rexahn Pharmaceuticals Presents New Preclinical Data on Supinoxin™ at the 2017 San Antonio Breast Cancer Symposium](#)

Financials [\[View all \]](#)

[Third Quarter Financial Results](#)

02/24/17

[Annual Report \(10-K\)](#)

02/24/17

[Proxy Statement \(DEF 14A\)](#)

11/03/17

[Quarterly Report \(10-Q\)](#)

08/04/17

[Quarterly Report \(10-Q\)](#)

05/03/17

[Quarterly Report \(10-Q\)](#)